2018-09-07T13:30:25-05:00 2017-12-31 043077056 MOODY FAMIGLIETTI & ANDRONICO LLP 1 HIGHWOOD DRIVE TEWKSBURY MA 01876 990 2017-01-01 451623549 UNITIO INC UNIT 6178926100 11 AVENUE DE LAFAYETTE NO 5TH FL BOSTON MA 02111 DARA SCHUSTER CURRENT CEO 6178926100 2018-08-30 1 JOYCE RIPIANZI CPA P00548581 9785575300 2018-08-30 64.27.39.203 2018-08-30 07:11:14 ED P 8190BC785C906750B3DDABDD0E4ED850B6448B4A 8190BC785C906750B3DDABDD0E4ED850B6448B4A 2017 2018-06-14 16:35:46Z DANA A BALL 11 AVENUE DE LAFAYETTE NO 5TH FL BOSTON MA 02111 2553528 0 X WWW.UNITIO.ORG; WWW.T1DEXCHANGE.ORG X 2011 DE SEE SCHEDULE O 9 8 43 0 0 0 11084716 1708747 1065528 826196 22623 18585 0 0 12172867 2553528 0 0 0 0 2980164 3794120 0 0 405384 2919718 3249475 5899882 7043595 6272985 -4490067 13249795 8933069 649618 822959 12600177 8110110 X UNITIO, INC. ("UNITIO") IS A NONPROFIT ORGANIZATION WHO UNITES THOSE AFFECTED BY DISEASE WITH THOSE DEDICATED TO ADVANCING BETTER CARE AND TREATMENTS TO CREATE A FASTER PATH TO IMPROVED OUTCOMES. THE ORGANIZATION'S FLAGSHIP PROGRAM, T1D EXCHANGE, IS IMPROVING THE QUALITY OF LIFE FOR PEOPLE WITH TYPE 1 DIABETES BY DRIVING FASTER, BETTER RESEARCH THAT FACILITATES DISCOVERY, ACCELERATES TREATMENTS, AND IMPROVES CLINICAL CARE. THE PROGRAM STRIVES TO ACCELERATE NEW TREATMENTS AND IMPROVE CARE FOR PEOPLE WITH TYPE 1 DIABETES AS FAST AS HUMANLY POSSIBLE. 0 0 5500291 826196 THE FIRST PROGRAM OF UNITIO WAS THE CREATION OF THE T1D EXCHANGE. T1D EXCHANGE WAS BORN OUT OF THE NEED TO IMPROVE OUTCOMES FOR PEOPLE WITH TYPE 1 DIABETES AS FAST AS HUMANLY POSSIBLE. TO HELP RESEARCHERS OVERCOME THE MANY OBSTACLES REQUIRED TO ACCELERATE ALL ASPECTS OF DRUG AND DEVICE DEVELOPMENT, THE MODEL OFFERS EASY ACCESS TO AGGREGATED CLINICAL, BIOLOGICAL, PATIENT-REPORTED OUTCOMES AND ELECTRONIC HEALTH RECORD DATA, ALL WHILE FOSTERING COLLABORATION AMONG PATIENTS, PHYSICIANS, RESEARCHERS AND INDUSTRY. TO SUPPORT ITS STRATEGIC INITIATIVES, T1D EXCHANGE HAS BUILT THE FOLLOWING RESOURCES TO DRIVE THE DELIVERY OF NEW TREATMENTS AND BETTER CARE FASTER TO PATIENTS. (1) PATIENT-CENTERED RESEARCH IS SUPPORTED BY OUR ONLINE COMMUNITY, GLU, AMPLIFIES THE COLLECTIVE VOICE OF PEOPLE LIVING WITH TYPE 1 DIABETES. OUR MORE THAN 20,000 T1D PATIENTS, CAREGIVERS, AND SUPPORTERS CAN CONNECT, OFFER PEER-TO-PEER SUPPORT, ACCESS EDUCATIONAL RESOURCES, AND PARTICIPATE DIRECTLY IN SURVEYS, DISCUSSIONS, AND RESEARCH THAT MAY ULTIMATELY BENEFIT THEIR OWN HEALTH. THIS REAL-WORLD DATA ADDS FRESH NEW PERSPECTIVES TO TRADITIONAL METHODS OF INQUIRY. OUR CLINIC REGISTRY FEATURES WELL-CHARACTERIZED DATA FROM 32,000 ENROLLED PATIENTS FROM OUR CLINIC NETWORK. WE CONTINUE TO EXPAND OUR REACH INTO THE T1D COMMUNITY TO GROW OUR CIRCLES OF ENGAGED PARTICIPANTS. (2) COLLABORATIVE SCIENCE IS SUPPORTED BY: THE T1D EXCHANGE BIOBANK, WHICH ACTS AS A CATALYST FOR THE EXCHANGE OF KNOWLEDGE AND COLLABORATION. A WORLD-CLASS RESOURCE FOR INNOVATIVE RESEARCH, THE BIOBANK CONTAINS THOUSANDS OF BIOLOGICAL SPECIMENS AND PATIENT DATA TO HELP BETTER UNDERSTAND CAUSES OF TYPE 1 DIABETES AND RESPONSES TO THERAPY. (3) IMPROVING QUALITY CARE IS SUPPORTED BY: OUR QUALITY IMPROVEMENT (QI) INITIATIVE WHERE T1D EXCHANGE AIMS TO DEVELOP, TEST, AND IMPLEMENT AN INTEGRATED CLINICAL CARE AND RESEARCH SYSTEM IN TYPE 1 DIABETES. (4) ACCELERATING INNOVATION IS SUPPORTED BY: THE T1D EXCHANGE DIABETES INNOVATION CHALLENGE, A COMPETITION DESIGNED TO PRESENT THE MOST PROMISING INNOVATIONS IN TYPE 1 DIABETES TO OUR NETWORK OF FUNDERS, INVESTORS, AND PARTNERS FROM ACADEMIA AND INDUSTRY. PARTICIPATING ORGANIZATIONS CAN WIN AWARDS FOR THEIR INNOVATIONS AND MAKE CONNECTIONS THAT MAY HELP THEM ADVANCE TO THE NEXT STAGE OF DEVELOPMENT.SINCE OUR FOUNDING IN 2010, THE T1D EXCHANGE HAS GROWN INTO A LEADING TYPE 1 DIABETES RESOURCE IN THE RESEARCH, MEDICAL, AND HEALTHCARE INNOVATION COMMUNITIES. WE'VE COMPLETED SEVERAL LARGE-SCALE CLINICAL STUDIES - AND HELPED ACCELERATE A POTENTIALLY GAME-CHANGING TREATMENT FOR SEVERE HYPOGLYCEMIA.OUR PATIENT-CENTERED RESEARCH FINDINGS HAVE SIGNIFICANTLY GROWN THE KNOWLEDGE BASE ABOUT LIFE WITH TYPE 1 DIABETES AND AT TIMES EVEN CHALLENGED CONVENTIONAL SCHOOLS OF THOUGHT; RESULTING IN MORE INFORMED RESEARCH, MORE MEANINGFUL STUDIES ON UNMET NEEDS, AND IMPROVED CARE. OUR WORK CONTINUES TO EVOLVE AS WE GROW OUR PATIENT-CENTERED COHORTS, EXPAND OUR RESOURCES, AND DEVELOP NEW AND IMPACTFUL WAYS TO COLLABORATE ACROSS THE T1D ECOSYSTEM. HERE ARE SOME OF RECENT HIGHLIGHTS OF OUR WORK:IN 2017, WE ENABLED THREE INNOVATIVE COMPANIES TO RECEIVE FINANCIAL AID AND IN-KIND SUPPORT TO ADVANCE THE DEVELOPMENT OF THEIR NOVEL PRODUCTS. OUR PATIENT-CENTERED RESEARCH DATA HELPED TO SECURE APPROVAL TO USE CGM (CONTINUOUS GLUCOSE MONITORING) SYSTEMS WITHOUT CONFIRMATORY READING FROM BLOOD GLUCOSE MONITORING; SUPPORTING FDA'S DECISION IN LATE 2016 TO EXPAND THE INDICATION FOR THE DEXCOM G5 CGM SYSTEMS AND REMOVING THE KEY OBSTACLE IN EARLY 2017 THAT SECURED CGM COVERAGE FROM MEDICARE/MEDICAID. STATE WORKERS WITH TYPE 1 DIABETES IN WASHINGTON ARE RECEIVING MORE BLOOD GLUCOSE STRIPS PER DAY AS A RESULT OF OUR DATA. OUR ONLINE COMMUNITY, GLU, HAS ALSO BEEN USED TO SUCCESSFULLY RESCUE TWO INDUSTRY STUDIES AND ONE NIH FUNDED STUDY THAT COULD NOT MEET INITIAL STUDY RECRUITMENT GOALS. A LARGE T1D EXCHANGE STUDY CONFIRMED THE PRESENCE OF C-PEPTIDE IN PATIENTS ACROSS A WIDE AGE SPECTRUM. THIS DECREASES THE RISKS OF MISDIAGNOSING TYPE 1 AS THE MORE COMMON TYPE 2 DIABETES, AND MAY HELP IMPROVE TREATMENTS TO CONTROL GLUCOSE LEVELS. WHAT'S MORE, THE STUDY SUPPORTS ACCESS TO INSULIN PUMPS FOR AS MANY AS 10% OF TYPE 1 DIABETES PATIENTS OVERALL AND 20% OF THOSE DIAGNOSED AS ADULTS, WHO MANY NOT HAVE MET MEDICARE, MEDICARE, MEDICAID, AND MANY PRIVATE INSURER'S CRITERIA FOR AN INSULIN PUMP. T1D EXCHANGE IS WIDELY RECOGNIZED IN THE GLOBAL MEDICAL COMMUNITY AND HAVE GIVEN WELL OVER 100 PRESENTATIONS AT LEADING MEDICAL, SCIENTIFIC, AND ADVOCACY EVENTS ACROSS THE GLOBE AND PUBLISHED NEARLY 50 MANUSCRIPTS IN KEY PEER-REVIEWED JOURNALS. IN ADDITION THESE GROUNDBREAKING RESEARCH STUDIES, THE T1D EXCHANGE CONTINUE TO FOLLOW OUR REGISTRY COHORT AND PROVIDE ONGOING SUPPORT TO OUR 30,000+ LIVES OF PATIENTS, CAREGIVERS AND INDUSTRY PARTNERS THROUGH NUMEROUS ARTICLES WITHIN GLU AND THE NATIONAL DIABETES COMMUNITY; PARTICIPATION AND PRESENTATION AT NATIONAL CONFERENCES SUCH AS ADA; AND NATIONAL AND LOCAL COMMUNITY EVENTS SUCH AS THE T1D EXCHANGE ANNUAL MEETING. 5500291 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 42 0 1 43 1 0 0 0 0 0 0 0 0 0 0 X 9 8 0 0 0 0 1 1 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MA AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MI MN OK OR PA RI SC TN UT VA WA WV WI AZ DE ID IA LA MS OH ND MO NV NE NH NJ NY NC X THE ORGANIZATION 6178926100 11 AVENUE DE LAFAYETTE 5TH FLOOR BOSTON MA 02111 ABBIE CELNIKER DIRECTOR 2.00 2.00 X 0 0 0 KEITH RYAN DIRECTOR 2.00 2.00 X 0 0 0 MARIJANE NORRIS-GEARY DIRECTOR 2.00 2.00 X 0 0 0 DEBORAH PINE DIRECTOR 2.00 X 0 0 0 HAYDON KEITNER DIRECTOR 2.00 X 0 0 0 JENNIFER MCCABE DIRECTOR 2.00 X 0 0 0 JAY MOHR DIRECTOR 2.00 X 0 0 0 DANA BALL CEO/ PRESIDENT / SECRETARY 40.00 2.00 X X 327235 0 15716 KIM PEMBLE TREASURER 2.00 X X 0 0 0 JASON DANA COSTA CHIEF FINANCIAL OFFICER 40.00 2.00 X 188993 0 21178 JAYA PLMANABHAN CHIEF TECHNOLOGY OFFICER 40.00 X 204772 0 19141 GEORGE SERBEDZIJA VP, STRATEGIC AND CORPORAT 40.00 X 203993 0 8655 WENDY WOLF BIOBANK DIRECTOR 40.00 X 202146 0 7457 HENRY ANHALT CHIEF MEDICAL OFFICER (THRU 5/19/17) 40.00 X 190801 0 6332 JILL PETRIE DIR OF COMMUNICATIONS (THRU 12/29/17) 40.00 X 160354 0 6138 1478294 0 84617 11 0 1 0 NEWFIRE LLC 210 BROADWAY ST SUITE 201 CAMBRIDGE MA 02139 SOFTWARE DESIGN & DEVELOPMENT 561848 COMMCREATIVE 75 FOUNTAIN STREET FRAMINGHAM MA 01702 MARKETING 190305 UNIVERSITY OF WASHINGTON GRANT/CONTRACT ACCOUNTING BOX 3549 SEATTLE WA 98195 RESEARCH 171292 RECON STRATEGY ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 CONSULTING 151000 NIXON PEABODY LLP 100 SUMMMER STREET BOSTON MA 02110 LEGAL SERVICES 114470 6 84970 1623777 1708747 CONTRACT SERVICE REVEN 900099 826196 826196 826196 18585 18585 2553528 826196 0 18585 419281 51443 282100 85738 2842983 2537507 219324 86152 59641 56264 1976 1401 229746 179721 29106 20919 242469 186701 43644 12124 62706 62706 32210 32210 363552 312007 8315 43230 384970 291877 50590 42503 266971 192986 30562 43423 502907 263545 215206 24156 284519 226449 28594 29476 50319 39638 5522 5159 320670 303936 11953 4781 32007 20978 6993 4036 PROGRAM SERVICES 625176 623347 1682 147 SUBCONTRACTORS 153746 153746 RECRUITMENT AND TRAININ 138247 60146 75962 2139 BAD DEBT EXPENSE 23639 23639 7836 7836 7043595 5500291 1137920 405384 X 569481 901719 3502138 1581319 8193616 3909832 136147 379378 68919 46382 327947 154329 73964 173618 1006474 490925 655627 214605 278720 13249795 8933069 415575 462372 200000 150000 6250 100000 27793 110587 649618 822959 X 3042773 3222040 9557404 4888070 12600177 8110110 13249795 8933069 -4490067 0 X X 0 1 X 1 0 X 210000 1077959 7577245 11084716 1708747 21658667 210000 1077959 7577245 11084716 1708747 21658667 8533515 13125152 18602 1074 12210 22623 18585 73094 21731761 8629363 0.60400 0.71470 X 96621 14116 82505 231326 140213 91113 173618 DEFERRED RENT 73207 OFFICERS RETIREMENT PLAN LIABILITY 37380 110587 X 2568977 15449 15449 2553528 0 2553528 7059044 15449 15449 7043595 0 7043595 PART X, LINE 2: THE ORGANIZATION IS A NONPROFIT ORGANIZATION AS DESCRIBED IN SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND EACH ARE EXEMPT FROM FEDERAL AND STATE INCOME TAXES. AS A RESULT, NO PROVISION FOR INCOME TAXES IS PRESENTED IN THESE FINANCIAL STATEMENTS. HOWEVER, IN CERTAIN CIRCUMSTANCES, THE ORGANIZATION MAY BE SUBJECT TO FEDERAL AND STATE INCOME TAXES FOR PROFITS GENERATED FROM UNRELATED TRADE OR BUSINESS INCOME. AS DECEMBER 31, 2017, MANAGEMENT'S POSITION IS THAT THE ORGANIZATION DOES NOT HAVE ANY LIABILITIES ASSOCIATED WITH UNRELATED TRADE OR BUSINESS INCOME. THE ORGANIZATION ASSESSES THE RECORDING OF UNCERTAIN TAX POSITIONS BY EVALUATING THE MINIMUM RECOGNITION THRESHOLD AND MEASUREMENT REQUIREMENTS A TAX POSITION MUST MEET BEFORE BEING RECOGNIZED AS A BENEFIT IN THE CONSOLIDATED FINANCIAL STATEMENTS. THE ORGANIZATION'S POLICY IS TO RECOGNIZE INTEREST AND PENALTIES ACCRUED ON UNCERTAIN TAX POSITIONS AS A COMPONENT OF INCOME TAX EXPENSES, IF ANY, IN ITS STATEMENTS OF ACTIVITIES. X X 1 0 0 0 0 0 0 0 0 DANA BALL CEO/ PRESIDENT / SECRETARY 327235 0 0 0 0 0 9377 0 6339 0 342951 0 0 0 JASON DANA COSTA CHIEF FINANCIAL OFFICER 188993 0 0 0 0 0 5880 0 15298 0 210171 0 0 0 JAYA PLMANABHAN CHIEF TECHNOLOGY OFFICER 204772 0 0 0 0 0 3556 0 15585 0 223913 0 0 0 GEORGE SERBEDZIJA VP, STRATEGIC AND CORPORAT 203993 0 0 0 0 0 6123 0 2532 0 212648 0 0 0 WENDY WOLF BIOBANK DIRECTOR 202146 0 0 0 0 0 6059 0 1398 0 209603 0 0 0 HENRY ANHALT CHIEF MEDICAL OFFICER (THRU 5/19/17) 190801 0 0 0 0 0 5749 0 583 0 197133 0 0 0 JILL PETRIE DIR OF COMMUNICATIONS (THRU 12/29/17 160354 0 0 0 0 0 4805 0 1333 0 166492 0 0 0 FORM 990, PART 1, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: T1D EXCHANGE WAS FOUNDED IN 2010 ON THE BELIEF THAT PEOPLE AFFECTED BY TYPE 1 DIABETES NEED BETTER SOLUTIONS FASTER - BETTER TREATMENTS AND BETTER CARE. THE NONPROFIT ORGANIZATION TAKES AN INNOVATIVE APPROACH THAT PUTS THE COMMUNITY OF PEOPLE TOUCHED BY TYPE 1 DIABETES AT THE CENTER OF RESEARCH THAT WILL MEANINGFULLY IMPACT THEIR LIVES. SINCE OUR FOUNDING IN 2010, WE'VE BEEN WORKING TO ACCELERATE NEW THERAPIES AND IMPROVE THE QUALITY OF CARE FOR PEOPLE WITH TYPE 1 DIABETES. TODAY, T1D EXCHANGE IS STRATEGICALLY FOCUSED ON THE FOLLOWING INITIATIVES TO ADVANCE OUR MISSION: (1) PATIENT-CENTERED RESEARCH: AT T1D EXCHANGE, WE ARE IDENTIFYING, BUILDING, AND ENGAGING LARGE COHORTS OF PATIENTS AND CAREGIVERS FROM THE T1D COMMUNITY WHO ARE READY AND WILLING TO PARTICIPATE IN RESEARCH. (2) COLLABORATIVE SCIENCE: T1D EXCHANGE FOSTERS COLLABORATION AMONG VARIOUS SCIENTIFIC, RESEARCH AND INDUSTRY STAKEHOLDERS TO DEEPEN THE UNDERSTANDING OF TYPE 1 DIABETES AND EXPAND THE KNOWLEDGE BASE OF THE DISEASE. (3) IMPROVING QUALITY CARE: T1D EXCHANGE IS LEVERAGING ITS BROAD EXPERTISE TO DISCOVER IF WE CAN HELP CLINICS ACHIEVE BETTER OUTCOMES FOR THEIR PATIENTS MORE EFFICIENTLY AND EFFECTIVELY. OUR GOAL IS TO UNDERSTAND THE VARIABILITY OF OUTCOMES ACROSS A VARIED T1D POPULATION, AND TEST NEW WAYS TO IMPROVE OUTCOMES. (4) ACCELERATING INNOVATION: BREAKTHROUGHS CAN'T HAPPEN WITHOUT INNOVATION. THIS INITIATIVE AIMS TO ACCELERATE TRANSFORMATIVE T1D RESEARCH THROUGH THE ADVANCEMENT OF INNOVATIVE, NOVEL APPROACHES. THE GOAL IS TWO-FOLD: TO DISCOVER AND ADVANCE PROMISING SOLUTIONS FOR PEOPLE LIVING WITH T1D, WHILE REDUCING THE RISKS OF BRINGING THESE INNOVATIONS TO MARKET. FORM 990, PART VI, SECTION A, LINE 6 THE MEMBER IS THOSE PERSONS SERVING FROM TIME TO TIME AS THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A UNITIO IS A MEMBERSHIP CORPORATION. THE MEMBER IS THOSE PERSONS SERVING FROM TIME TO TIME AS THE BOARD OF DIRECTORS. IN SEPTEMBER 2015 THE BYLAWS OF UNITIO WERE AMENDED SO THAT ALL MEMBERS OF THE BOARD COLLECTIVELY HAVE THE POWER TO ELECT AND REMOVE BOARD OF DIRECTOR MEMBERS, CAN AMEND THE CERTIFICATE OF INCORPORATION AND ADOPT, AMEND AND REPEAL THE BY-LAWS OF THE ORGANIZATION. FORM 990, PART VI, SECTION B, LINE 11B PRIOR TO FILING FORM 990 THE COMPLETED FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION CONTINUALLY MONITORS AND ENFORCES THE CONFLICT OF INTEREST POLICY BY (1) REQUIRING ALL NEW BOARD MEMBERS TO SIGN THE POLICY AND IDENTIFY ANY CONFLICTS THAT MAY EXIST, AND (2) ANNUALLY RE-AFFIRM WITH ALL MEMBERS OF THE BOARD OF DIRECTORS AND IDENTIFY ANY CONFLICTS OF INTEREST THAT MAY HAVE OCCURRED IN THE PRIOR YEAR. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS IS RESPONSIBLE FOR THE YEARLY PERFORMANCE EVALUATION AND SALARY REVIEW OF THE EXECUTIVE DIRECTOR AND ANY EMPLOYEES EARNING $200,000 OR MORE. THE BOARD USES SALARY SURVEY'S AS A BENCHMARK FOR EACH POSITION, UTILIZING COMPARABLES FROM OTHER SIMILAR ORGANIZATIONS AND OTHER AVAILABLE DATA. FORM 990, PART VI, SECTION C, LINE 18 THE ORGANIZATION MAKES ITS FORM 1023, AND 990S AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART X, COLUMN A, LINE 27 & 28: CERTAIN ACCOUNTS IN THE DECEMBER 31, 2016 FINANCIAL STATEMENTS HAVE BEEN RECLASSIFIED FOR COMPARATIVE PURPOSES TO CONFORM TO THE PRESENTATION IN THE DECEMBER 31, 2017 FINANCIAL STATEMENTS. THE ORGANIZATION RECLASSIFIED AMOUNTS FROM TEMPORARILY RESTRICTED NET ASSETS TO UNRESTRICTED NET ASSETS ON THE CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AND STATEMENTS OF ACTIVITIES BY CORRECTING THE NET ASSETS RELEASED FROM RESTRICTION IN THE AMOUNT OF $251,333 DURING THE YEAR ENDED DECEMBER 31, 2016. FORM 990; PART XII;LINE 2C: THE ORGANIZATION HAS A COMMITTEE THAT ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF THE INDEPENDENT AUDITORS. THIS PROCESS HAS NOT CHANGED DURING THE YEAR. UNITIO SUPPORTING FOUNDATION INC 11 AVENUE DE LAFAYETTE 5TH FLOOR BOSTON MA 02111 475074602 BENEFITING AND SUPPORTING THE CHARITABLE ACTIVITIES OF UNITIO, INC. MA 501(C)3 LINE 12B, II UNITIO INC 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 UNITIO SUPPORTING FOUNDATION Q 221340 FMV